Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
3.0
Journals
CIMB
Special Issues
Advances in Drug Delivery: Molecular Mechanisms, Therapeutic Applications, and Technologies
cimb-logo
Submit to Special Issue Submit Abstract to Special Issue Review for CIMB Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances in Drug Delivery: Molecular Mechanisms, Therapeutic Applications, and Technologies

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Biochemistry, Molecular and Cellular Biology".

Deadline for manuscript submissions: 31 October 2026 | Viewed by 3313

Special Issue Editors

Dr. Wenhao Wang

E-Mail Website
Guest Editor
School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510275, China
Interests: transdermal drug delivery; pulmonary drug delivery; nanocarrier; molecular pharmaceutics
Special Issues, Collections and Topics in MDPI journals
Dr. Zhengwei Huang

E-Mail Website
Guest Editor
College of Pharmacy, Jinan University, Guangzhou 510632, China
Interests: inhalable nanomedicines; drug delivery; ferroptosis; biological fate
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Driven by our growing understanding of disease mechanisms, multiple innovative drug delivery systems have been proposed to enhance drug delivery efficiency and improve treatment outcomes. By comprehensively mapping the microenvironments of lesions, the complex interactions between drug carriers and biological factors can be revealed and predicted. Consequently, targeted delivery technologies, controlled-release systems, stimulus-responsive drug carriers, and biomimetic delivery systems have garnered significant attention in the treatment of tumors, inflammatory diseases, infections, and other conditions, paving the way for precision medication. Meanwhile, the molecular mechanisms underlying these novel drug delivery systems are being evaluated, to optimize further design and development.

This Special Issue will focus on the latest advancements in drug delivery systems, particularly underlying molecular mechanisms, enabling technologies, and corresponding therapeutic applications. We welcome submissions that clarify the molecular mechanisms behind interactions between drug carriers and biological systems, introduce strategies for overcoming delivery barriers, present novel stimulus-responsive drug delivery systems, and explore theranostic platforms. For this Special Issue, we encourage studies addressing clinical challenges or proposing proof-of-concept novel systems.

Dr. Wenhao Wang
Dr. Zhengwei Huang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug delivery
  • stimulus-responsive drug delivery systems
  • controlled-release drug delivery systems
  • theranostics
  • carrier–biological system interactions
  • delivery barriers
  • molecular mechanisms

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 4576 KB  
Article
Sublingual Dripping Pill Formulation of Ganoderma amboinense Fruiting Body Extract Attenuates CCl4-Induced Liver Fibrosis via Multi-Pathway Regulation
by Chin-Feng Liu, Chong-Ming Pan and Chun-Lin Lee
Curr. Issues Mol. Biol. 2025, 47(9), 697; https://doi.org/10.3390/cimb47090697 - 28 Aug 2025
Viewed by 1669
Abstract
Liver fibrosis remains difficult to treat, in part because many hepatoprotective triterpenoids suffer from poor oral bioavailability and lack of optimized delivery formats. Ganoderma amboinense is a rare “antler” reishi species long valued in Eastern traditions yet scarcely studied for its phytochemical and [...] Read more.
Liver fibrosis remains difficult to treat, in part because many hepatoprotective triterpenoids suffer from poor oral bioavailability and lack of optimized delivery formats. Ganoderma amboinense is a rare “antler” reishi species long valued in Eastern traditions yet scarcely studied for its phytochemical and pharmacological potential. Here, we report the first investigation of an ethanol-extracted G. amboinense sublingual dripping pill formulation (GDP) in a carbon-tetrachloride (CCl4)–induced mouse model of liver fibrosis. Mice treated with GDP at one- and five-times the human equivalent dose were compared to groups receiving unprocessed G. amboinense powder (GP) or purified ganoderic acid A (GA-A). GDP significantly prevented CCl4-induced weight loss and hepatomegaly, normalizing liver-to-body weight ratios and serum AST/ALT activities (p < 0.05). Histological evaluation showed that GDP markedly reduced hepatocellular necrosis and collagen deposition, restoring tissue architecture. Furthermore, GDP suppressed hepatic expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, COX-2) and profibrotic markers (TGF-β1, CTGF, α-SMA) to levels comparable with or superior to GA-A. These results demonstrate that a dripping pill dosage form can effectively deliver G. amboinense triterpenoids and unlock their hepatoprotective activity, supporting further development of GDP as a novel liver-support nutraceutical. Full article
(This article belongs to the Special Issue Advances in Drug Delivery: Molecular Mechanisms, Therapeutic Applications, and Technologies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

27 pages, 1527 KB  
Review
Recent Advances in Oral Drug Delivery Systems for BCS III Drugs
by Junpeng Yu, Peng Wang, Zishen Bei, Lulu Tan, Jiaxin Wang, Guimin Qin, Yuying Huang, Shuhua Peng, Shen Liu, Jielan Huang, Xiaoxiu Shi, Qiujie Chen, Jinyan Xian, Yuanle Shen, Ting Xia and Jianfang Feng
Curr. Issues Mol. Biol. 2026, 48(1), 63; https://doi.org/10.3390/cimb48010063 - 5 Jan 2026
Viewed by 1123
Abstract
Oral drugs classified under Class III of the Biopharmaceutics Classification System (BCS) are defined by high aqueous solubility yet low intestinal permeability. Their restricted oral bioavailability arises not from inadequate dissolution, but is primarily governed by the intestinal permeability barrier, coupled with substantial [...] Read more.
Oral drugs classified under Class III of the Biopharmaceutics Classification System (BCS) are defined by high aqueous solubility yet low intestinal permeability. Their restricted oral bioavailability arises not from inadequate dissolution, but is primarily governed by the intestinal permeability barrier, coupled with substantial inter-individual variability in absorption. This review adopts the intestinal permeability barrier as its core analytical framework to dissect the key determinants of oral absorption for BCS III drugs, while presenting a comparative and critical evaluation of prevailing bioavailability enhancement strategies. From perspectives including mechanism of action, achievable magnitude of enhancement, applicable physicochemical and physiological conditions, and translational feasibility, the intrinsic mechanistic limitations and applicable boundaries of distinct strategies are delineated. Finally, this paper concludes that the absorption barriers of BCS III drugs cannot be universally surmounted by a single strategy, emphasizing the significance of mechanism-guided strategy selection for the rational design of oral drug delivery systems. In doing so, it provides a foundational basis for the rational development of oral delivery systems tailored to BCS III drugs. Full article
(This article belongs to the Special Issue Advances in Drug Delivery: Molecular Mechanisms, Therapeutic Applications, and Technologies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop